Literature DB >> 21727767

Cytomegalovirus infections in unrelated cord blood transplantation in pediatric patients: incidence, risk factors, and outcomes.

Sami Al-Hajjar1, Amal Al Seraihi, Saleh Al Muhsen, Mouhab Ayas, Suliman Al Jumaah, Abdullah Al Jefri, Mohamed Shoukri, Hassan El Solh.   

Abstract

BACKGROUND AND OBJECTIVES: Stem cells from umbilical cord blood (CB) have increasingly become a viable alternate source of progenitor cells for hematopoietic cell transplantation (HSCT). Cytomegalovirus (CMV) is thought to contribute significantly to HSCT morbidity and mortality. DESIGN AND
SETTING: Retrospective case-control study in patients at tertiary care center. PATIENTS AND METHODS: We determined the incidence, risk factors and outcomes for CMV infection and disease after unrelated cord blood transplantation (UCBT) in children.
RESULTS: Between 2003 and 2007, 73 pediatric patients underwent UCBT and 68% of recipients were CMV seropositive. The overall incidence of CMV infection, early and late CMV infection was 58.9% (43/73), 62.8% (27/43), and 37.4% (16/43), respectively. in patients with early CMV infection, 6 of 27 (22%) patients progressed to develop CMV end-organ disease including pneumonitis and retinitis. High levels CMV antigenemia ≥70 infected cells by pp65 antigenemia assay + PMNs, P=.237) were associated with a higher risk of progression to CMV disease. The development of CMV infections was higher in CMV-seropositive recipients (P<.001) and in those who developed graft-versus-host-diseases (GVhD) (P<.001). other risk factors for CMV infection include the use of high-dose corticosteroids (P<.001) and older age of the recipient at the time of transplant (P<.002). Late CMV infection was strongly associated with a previous history of early CMV infection (P<.001).
CONCLUSION: CMV infection is a significant complication in UCBT recipients in pediatric patients and is associated with an increase in transplant-related morbidity and mortality. Risk factors for CMV infections after UCBT include GvHD, use of corticosteroids, underlying diseases (hematologic malignancies) and older age. Late CMV infection was strongly associated with a previous history of CMV infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21727767     DOI: 10.5144/1658-3876.2011.67

Source DB:  PubMed          Journal:  Hematol Oncol Stem Cell Ther


  3 in total

1.  Risk factors for cytomegalovirus gastrointestinal diseases in adult patients with cancer.

Authors:  J-H Ko; K R Peck; W J Lee; K Huh; J R Yoo; K Kim; S Y Cho; Y E Ha; C-I Kang; D R Chung; C W Jung; Y-H Kim; N Y Lee; K-M Kim; J-H Song
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-23       Impact factor: 3.267

2.  The Current Status of Cytomegalovirus (CMV) Prevalence in the MENA Region: A Systematic Review.

Authors:  Hassan Al Mana; Hadi M Yassine; Nadin N Younes; Anjud Al-Mohannadi; Duaa W Al-Sadeq; Dalal Alhababi; Elham A Nasser; Gheyath K Nasrallah
Journal:  Pathogens       Date:  2019-10-31

3.  Cytomegalovirus infection may be oncoprotective against neoplasms of B-lymphocyte lineage: single-institution experience and survey of global evidence.

Authors:  Marko Janković; Aleksandra Knežević; Milena Todorović; Irena Đunić; Biljana Mihaljević; Ivan Soldatović; Jelena Protić; Nevenka Miković; Vera Stoiljković; Tanja Jovanović
Journal:  Virol J       Date:  2022-09-29       Impact factor: 5.913

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.